Eylea 40 mg/mL solution for injection in a vial clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
This study looks at a new version of Eylea (a medicine for eye problems) to see if it's safe and works well for people with blurry vision caused by fluid build-up at the back of their eye. It compares the new version to the standard treatment.
For: Macular edema secondary to retinal vein occlusionFrance · Slovakia · Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(20275) An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090
This study is looking at the long-term health of children, up to five years old, who received treatment for an eye condition called retinopathy of prematurity (ROP). Specifically, it will check their eyesight and overall development to see how well they are doing after treatment.
For: Retinopathy of prematuritySweden · Italy · Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
This study is looking into a new treatment, RBS-001, for a specific eye condition called wet age-related macular degeneration (wet AMD). It compares RBS-001 with an existing treatment, Eylea, to see if it works as well or better, and if it's safe for patients.
For: Neovascular age-related macular degeneration (nAMD)Bulgaria · Croatia · Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
TELeMAC - Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1
This study looks at how well a medicine called aflibercept (Eylea) works compared to a dummy treatment for a rare eye condition called macular telangiectasia type 1. Researchers want to see if it can improve swelling at the back of the eye and help sight.
For: macular telangiectasia type 1France